Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)	Convertible Preferred Stock Series A-1 Preferred Stock	Convertible Preferred Stock Series A-1	MTTR, LLC (“MTTR”) Common stock repurchase note	MTTR, LLC (“MTTR”) Additional Paid-in Capital	Common stock repurchase note	Additional Paid-in Capital	Accumulated Deficit	Total
Balance, beginning at Sep. 30, 2018	$ 4,734,416				$ 90,275	$ 190,672,166	$ (216,307,363)	$ (25,544,922)
Balance, beginning (in shares) at Sep. 30, 2018		60,203			9,027,491
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of common stock (in shares)								2,680,390
Proceeds from exercise of common stock warrants					$ 9	(9)
Proceeds from exercise of common stock warrants (in shares)					909
Private placement sale of common stock and common stock warrants, net of costs					$ 26,804	19,781,513		$ 19,808,317
Private placement sale of common stock and common stock warrants, net of costs (in shares)					2,680,390
Issuance of vested restricted stock units					$ 4	(4)
Issuance of vested restricted stock units (in shares)					446			446
Issuance of common stock in connection with conversion of senior secured notes					$ 504	401,464		$ 401,968
Issuance of common stock in connection with conversion of senior secured notes (in shares)					50,394
Series A-1 convertible preferred stock dividends and related settlement	304,779					(304,779)		(304,779)
Series A-1 convertible preferred stock dividends and related settlement (in shares)		3,047
Stock-based compensation expense						1,140,031		1,140,031
Accrued directors fees settled in fully vested stock options						49,121		49,121
Net loss							(19,986,640)	(19,986,640)
Balance, ending at Mar. 31, 2019	$ 5,039,195				$ 117,596	211,739,503	(239,943,261)	(28,086,162)
Balance, ending (in shares) at Mar. 31, 2019	63,250	63,250			11,759,630
Balance, beginning at Dec. 31, 2018	$ 4,884,924				$ 106,365	203,237,836	(229,698,465)	(26,354,264)
Balance, beginning (in shares) at Dec. 31, 2018	61,708				10,636,421
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from exercise of common stock warrants					$ 3	(3)
Proceeds from exercise of common stock warrants (in shares)					358
Private placement sale of common stock and common stock warrants, net of costs					$ 10,721	7,986,738		7,997,459
Private placement sale of common stock and common stock warrants, net of costs (in shares)					1,072,156
Issuance of vested restricted stock units					$ 3	(3)
Issuance of vested restricted stock units (in shares)					301
Issuance of common stock in connection with conversion of senior secured notes					$ 504	401,464		401,968
Issuance of common stock in connection with conversion of senior secured notes (in shares)					50,394
Series A-1 convertible preferred stock dividends and related settlement	$ 154,271					(154,271)		(154,271)
Series A-1 convertible preferred stock dividends and related settlement (in shares)	1,542
Stock-based compensation expense						267,742		267,742
Net loss							(10,244,796)	(10,244,796)
Balance, ending at Mar. 31, 2019	$ 5,039,195				$ 117,596	211,739,503	(239,943,261)	(28,086,162)
Balance, ending (in shares) at Mar. 31, 2019	63,250	63,250			11,759,630
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of adoption of ASU 2014-09 (Topic 606)							(3,649,258)	(3,649,258)
Balance, beginning at Sep. 30, 2019	$ 5,359,404				$ 286,100	238,064,947	(254,480,408)	(16,129,361)
Balance, beginning (in shares) at Sep. 30, 2019	66,451				28,609,995
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with exercise of warrants					$ 130,034	1,008,866		1,138,900
Issuance of common stock in connection with exercise of warrants (in shares)					13,003,414
Sale of common stock, net of issuance costs					$ 100,591	9,096,357		9,196,948
Sale of common stock (in shares)			7,244,739		10,059,056
Issuance of common stock in connection with conversion of stockholder notes					$ 14,753	1,533,673		$ 1,548,426
Issuance of common stock in connection with conversion of stockholder notes (in shares)					1,475,258
Issuance of vested restricted stock units					$ 1	(1)
Issuance of vested restricted stock units (in shares)					109			109
Series A-1 convertible preferred stock dividends and related settlement	$ 166,133					(166,133)		$ (166,133)
Series A-1 convertible preferred stock dividends and related settlement (in shares)	1,661
Stock-based compensation expense						664,016		664,016
Net loss							(22,303,015)	(22,303,015)
Conversion of Series A-1 convertible preferred stock to common stock (in shares)					29,358,621
Balance, ending at Mar. 31, 2020					$ 897,512	255,361,229	(276,783,423)	(20,524,682)
Balance, ending (in shares) at Mar. 31, 2020					89,751,192
Balance, beginning at Dec. 31, 2019	$ 5,525,537				$ 384,309	239,766,786	(271,083,356)	(30,932,261)
Balance, beginning (in shares) at Dec. 31, 2019	68,112				38,430,924
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with exercise of warrants					$ 46,579	1,034,043		1,080,622
Issuance of common stock in connection with exercise of warrants (in shares)					4,657,852
Sale of common stock, net of issuance costs			$ 72,447	$ (72,447)	$ 100,591	9,096,357		9,196,948
Sale of common stock (in shares)			7,244,739		10,059,056
Series A-1 convertible preferred stock dividends and related settlement (in shares)		1,661
Stock-based compensation expense						304,539		304,539
Net loss							(5,700,067)	(5,700,067)
Conversion of Series A-1 convertible preferred stock to common stock	$ (5,525,537)				$ 293,586	5,231,951		5,525,537
Conversion of Series A-1 convertible preferred stock to common stock (in shares)	(68,112)				29,358,621
Balance, ending at Mar. 31, 2020					$ 897,512	$ 255,361,229	$ (276,783,423)	$ (20,524,682)
Balance, ending (in shares) at Mar. 31, 2020					89,751,192